BofA Securities analyst Tim Anderson raised the price target on Gilead Sciences (NASDAQ: GILD) to $162.00 (from $154.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Gilead Sciences (GILD) PT Raised to $165 at OppenheimerFebruary 11, 2026 8:33 AM Gilead Sciences (GILD) PT Raised to $165 at Wells FargoFebruary 11, 2026 8:27 AM Gilead Sciences (GILD) PT Raised to $155 at Deutsche BankFebruary 11, 2026 7:32 AM Gilead Sciences (GILD) PT Raised to $145 at BairdFebruary 11, 2026 7:17 AM Gilead Sciences (GILD) PT Raised to $170 at NeedhamFebruary 11, 2026 7:07 AM Gilead Sciences (GILD) PT Raised to $152 at Truist SecuritiesFebruary 11, 2026 7:05 AM Gilead Sciences (GILD) PT Raised to $177 at ScotiabankFebruary 11, 2026 6:26 AM Gilead Sciences (GILD) PT Raised to $160 at BMO CapitalFebruary 11, 2026 5:08 AM Goldman Sachs Reiterates Neutral Rating on Gilead Sciences (GILD)February 11, 2026 5:04 AM Stocks expected to have increasing option volume: GILD HOOD NET EW ZG Z LYFT FRSH MCD TMUS SHOP HLT KHC THC U BWA ULCC HUM THC BWA ULC February 11, 2026 4:27 AM After-hours movers: Robinhood, Ford, Lyft, Mattel, Cloudflare, UpstartFebruary 10, 2026 4:40 PM Gilead Sciences (GILD) Tops Q4 EPS by 1c, Offers GuidanceFebruary 10, 2026 4:03 PM Form 8-K GILEAD SCIENCES, INC. For: Feb 10February 10, 2026 4:02 PM